Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Research & Development data on file, last reported at $41.7 million in Q1 2026.

• Research & Development for Q1 2026 came in at $41.7 million, up 12.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.1 million (up 17.66% YoY), and the FY2025 annual result was $167.3 million, down 29.68% from the prior year.
• Research & Development eased to $41.7 million in Q1 2026 per RYTM's latest filing, from $42.0 million in the prior quarter.
• Over five years, Research & Development peaked at $128.7 million in Q1 2024 and troughed at $21.1 million in Q3 2022.
• A 5-year average of $40.6 million and a median of $37.0 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 239.08% in 2024, then slumped 71.26% in 2025.
• A 5-year view of Research & Development shows it stood at $23.5 million in 2022, then grew by 26.94% to $29.9 million in 2023, then soared by 37.72% to $41.2 million in 2024, then climbed by 2.1% to $42.0 million in 2025, then dropped by 0.73% to $41.7 million in 2026.
• Business Quant data shows RYTM's Research & Development at $41.7 million in Q1 2026, $42.0 million in Q4 2025, and $46.0 million in Q3 2025.